Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) have earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $19.50.

IMMX has been the topic of a number of recent research reports. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. HC Wainwright raised their target price on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Morgan Stanley initiated coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 target price on the stock. Citizens Jmp restated a “market outperform” rating and issued a $23.00 target price on shares of Immix Biopharma in a report on Friday, March 27th. Finally, Mizuho raised their target price on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Monday, March 30th.

Immix Biopharma Stock Up 3.2%

IMMX stock opened at $8.74 on Wednesday. Immix Biopharma has a twelve month low of $1.94 and a twelve month high of $11.61. The stock’s 50 day moving average is $9.20 and its 200-day moving average is $7.68. The firm has a market capitalization of $475.54 million, a PE ratio of -9.50 and a beta of 0.10.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, equities research analysts anticipate that Immix Biopharma will post -0.7 earnings per share for the current fiscal year.

Institutional Trading of Immix Biopharma

Hedge funds have recently bought and sold shares of the business. Allworth Financial LP bought a new stake in Immix Biopharma during the fourth quarter worth $30,000. Mathes Company Inc. bought a new stake in Immix Biopharma during the fourth quarter worth $56,000. Balyasny Asset Management L.P. bought a new stake in Immix Biopharma during the fourth quarter worth $67,000. Kera Capital Partners Inc. bought a new stake in Immix Biopharma during the fourth quarter worth $68,000. Finally, Squarepoint Ops LLC bought a new stake in Immix Biopharma during the fourth quarter worth $112,000. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.